Company intelligence / Profile preview

Rarebird

Buffalo, New York, United Statesrarebird.coffee ↗

Ownership: Private
Employees: ~7
Development stage: Other

Overview

Rarebird has developed and commercialized coffee infused with paraxanthine instead of caffeine. Early customer feedback highlights reduced jitters, improved alertness without anxiety or sleep disruption. The company holds patents on Px use in coffee and is developing proprietary biotechnological methods to produce Px at scale. They have received strategic investment to expand operations after relocating headquarters to Buffalo, NY

Therapeutic areas: Psychiatry
Modalities: Small molecule (paraxanthine)Biologic (future plans for enzyme-catalyzed production)
Industry: Food & Nutrition

Partnerships

Participating in discussions with major coffee companies and other firms using caffeine products; no formal partnerships disclosed yet

Beyond the preview

Go deeper on Rarebird.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rarebird.

Explore the full profile